High-dose pilot study with the novel progestogen dienogestin patients with endometriosis.

High-dose dienogest (20 mg/day) was used for the treatment of endometriosis in women aged 18-52 years after laparoscopic and histological diagnosis of endometriosis and staging according to the revised American Fertility Society criteria. Treatment efficacy was analyzed objectively by second-look laparoscopy, and serum hormone measurements and evaluation of endometriosis-related symptoms were performed done and side-effects recorded. Compared with other high-dose progestin therapies, treatment with dienogest was shown to be effective even in stage IV endometriosis. The side-effect profile of the high-dose dienogest treatment appears to be highly favorable compared with other treatments. Neither the menopausal symptoms caused by therapy with gonadotropin-releasing hormone agonists nor the adverse androgen-related effects induced by danazol were observed. Therefore, long-term high-dose dienogest therapy can be recommended particularly for women with progressive endometriosis.
AuthorsA E Schindler, B Christensen, A Henkel, M Oettel, C Moore
JournalGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (Gynecol Endocrinol) Vol. 22 Issue 1 Pg. 9-17 (Jan 2006) ISSN: 0951-3590 [Print] England
PMID16522528 (Publication Type: Journal Article)
Chemical References
  • Hormone Antagonists
  • dienogest
  • Nandrolone
  • Adult
  • Endometriosis (drug therapy)
  • Female
  • Hormone Antagonists (administration & dosage, adverse effects)
  • Humans
  • Nandrolone (administration & dosage, adverse effects, analogs & derivatives)
  • Pilot Projects
  • Statistics, Nonparametric
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: